ArticleFrontiers in pharmacology2026
Acute bilateral vision and hearing loss following high-dose selenium ingestion: a case report.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Selenium is an essential trace element widely used in health supplements. Reported cases of selenium poisoning have mainly involved hair loss, nail changes, and liver dysfunction, whereas toxic encephalopathy is uncommon. To date, no cases of selenium poisoning causing vision or hearing loss have been reported. Case Presentation: We report a 27-year-old woman employed in health supplement research and development who was occupationally exposed to multiple selenium compounds. During product testing in April 2025, she ingested selenium-containing samples. Based on the product formulation and the recorded amount sampled, the estimated oral selenium intake was 40.146 mg; however, this value represents an exposure estimate rather than a directly measured absorbed dose. She subsequently developed multisystem toxicity, including toxic encephalopathy, bilateral vision loss, hearing loss, liver dysfunction, alopecia, nail changes, and radial bone marrow edema. Initial symptoms were nausea and vomiting, followed by hearing loss, impaired consciousness, vision loss, and liver dysfunction. The first post-exposure blood selenium concentration was 13,131.8 ng/mL, and the urinary selenium concentration was 20,756.1 ng/mL. Intervention and Outcome: Treatment included sedation, diuretics, corticosteroids, hyperbaric oxygen therapy, organ protection, neurotrophic support, anti-infective therapy, and nutritional support. Consciousness recovered within 2 weeks, and liver function normalized. Vision transiently improved but later worsened. At 35-week follow-up, the right eye had no light perception, the left eye had visual acuity of 20 cm, and hearing loss had progressed to complete deafness. Conclusion: Extremely high-dose selenium ingestion can cause toxic encephalopathy and previously unreported persistent vision and hearing loss. Early supportive treatment and measures promoting selenium elimination may improve some clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.